News & Updates
Excerpt from the Press Release: National Health Care Institute of the Netherlands-supported study to evaluate role of the HeartFlow Analysis in reducing unnecessary invasive procedures REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that physicians at Erasmus MC Hospital (Rotterdam NL) have enrolled the first three patients in the…
Read More
Excerpt from the Press Release: – Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients – All doses achieved target engagement above the threshold for predicted anti-fibrotic activity, with an observed dose-response relationship – PLN-74809 reached highly fibrotic regions of the lung and was bound to αvβ6 in IPF…
Read More
“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said Kamal Ramzipoor, CEO of R3 Vascular. Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity.…
Read More
Excerpt from the Press Release: Researchers at the University of California, San Diego (UCSD) have grown miniature human lungs in a lab dish that they say come the closest to mimicking the real thing—complete with all the myriad cell types found in the body. The small organoids of human tissue could help rapidly iterate the…
Read More
Excerpt from the Press Release: First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil. Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month. SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal…
Read More
Tantu will leverage Ginkgo’s foundries to accelerate strain construction as a key step toward human clinical trials Excerpt from the Press Release: BOSTON, Sept. 7, 2021 /PRNewswire/ — Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the…
Read More
Excerpt from the Press Release: RINCETON, N.J.–(BUSINESS WIRE)–The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the…
Read More
Excerpt from the Press Release: One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?